Cabaletta Bio presented new clinical data from 4 refractory pemphigus vulgaris patients treated with rese-cel without preconditioning, showing biologic activity and safety at the lowest dose.
Key takeaways
2 of 4 patients showed compelling clinical activity through 6 months follow-up at the lowest dose without preconditioning.
3 of 4 patients remained off all immunomodulators and steroids as of data cut-off April 2, 2026.
Complete peripheral B cell elimination was observed in 3 of 4 patients.
Safety profile: Grade 1 CRS in 1 patient, no ICANS observed.
Higher dose cohort enrollment initiated; durability data expected in H2 2026.